TACSTD2 and adenocarcinoma: In contrast to TROP2, CEACAM5 displayed a negative correlation with AR in CRPC–adenocarcinoma and was expressed in all NEPC clusters, suggesting that CEACAM5 is an actionable target for non–AR–driven disease (Figure 4D) (46).